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Abstract  
Background: Newer approaches to genetic-counselling are required for population-based 
testing. We compare traditional face-to-face genetic-counselling with a DVD-assisted 
approach for population-based BRCA1/2 testing. 
Methods:  
A Cluster-randomised non-inferiority trial in the London Ashkenazi-Jewish population 
Inclusion-criteria: Ashkenazi-Jewish men/women >18years; Exclusion-criteria: (a)known 
BRCA1/2 mutation, (b)previous BRCA1/2 testing, (c)first-degree-relative of BRCA1/2 carrier. 
Ashkenazi-Jewish men/women underwent pre-test genetic-counselling prior to BRCA1/2 
testing in the GCaPPS trial(ISRCTN73338115). Genetic-counselling clinics (clusters) were 
randomised to traditional counselling(TC) and DVD-based counselling(DVD-C) approaches. 
DVD-C involved a DVD presentation followed by shorter face-to-face genetic-counselling. 
Outcome measures included genetic-testing uptake, cancer risk perception, increase in 
knowledge, counselling time and satisfaction(GCSS-scale). Random-effects models 
adjusted for covariates compared outcomes between TC and DVD-C groups. One-sided 
97.5%CI was used to determine non-inferiority. Secondary-outcomes: relevance, 
satisfaction, adequacy, emotional impact & improved understanding with the DVD; cost-
minimisation analysis for TC and DVD-C approaches. 
 
Results: 936 individuals(clusters=256, mean-size=3.6) were randomised to TC 
(n=527,clusters=134) & DVD-C (n=409,clusters=122) approaches. Groups were similar at 
baseline, mean-age=53.9(S.D=15) years, women=66.8%, men=33.2%. DVD-C was non-
inferior to TC for increase in knowledge (d=-0.07;lower-97.5%CI=-0.41), counselling 
satisfaction (d=-0.38, 97.5%CI=1.2), risk perception (d=0.08;upper-97.5%CI=3.1). Group 
differences and CIs didn’t cross non-inferiority margins. DVD-C was equivalent to TC for 
uptake of genetic-testing (d=-3%;Lower/Upper 97.5%CI=-7.9%/1.7%) and superior for 
counselling time (20.4(CI=18.7,22.2) minutes reduction(p<0.005)). 98% people found the 
DVD length-&-information satisfactory. 85-89% felt it improved their understanding of 
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risks/benefits/implications/purpose of genetic-testing. 95% would recommend it to others. 
The cost of genetic-counselling for DVD-C=£7,787 and TC=£17,307. DVD-C resulted in 
cost-savings=£9,520(£14/volunteer). 
 
Conclusions: DVD-C is an effective, acceptable, non-inferior, time saving and cost-efficient 
alternative to TC. 
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Introduction 
Genetic testing for high-penetrance BRCA1/2 mutations is usually available to individuals 
from high-risk families fulfilling stringent family-history (FH) criteria following genetic-
counselling in specialized cancer genetic clinics. Recent studies show that a significant 
proportion of BRCA1/2 carriers lack a strong FH of cancer but can be identified through 
population-based approaches, not standard clinical care.[1, 2, 3] The GCaPPS (Genetic-
Cancer-Prediction through Population-Screening) randomised controlled trial (RCT) 
compared population screening (PS) with FH-based testing for BRCA1/2 mutations in 
Ashkenazi Jewish (AJ) individuals (ISRCTN73338115). We found that PS for BRCA1/2 
mutations in AJ population does not harm quality-of-life/psychological well-being[3] and is 
extremely cost-effective leading to 33days gain in life-expectancy and incremental cost-
effectiveness ratio(ICER)=‘-£2079/quality-adjusted-life-year(QALY)’ well below the 
£20,000/QALY NICE threshold.[4]  
 
Pre-test genetic counselling is a fundamental element of international guidelines[5] for 
informed decision making prior to genetic testing. A range of decision-aids varying from 
pamphlets, booklets, computer-based programmes, audiotapes, to web-based platforms 
have been used as adjuncts to counselling to facilitate decision making in high-risk 
populations. Decision-aids reduce decisional conflict and lead to an increase in knowledge, 
accuracy of perceived benefits/harms, participation in decision making process and ability to 
make informed value-based choices.[6, 7] In addition group-based and telephone 
counselling approaches have been found to be beneficial and non-inferior in high-risk 
women.[8, 9, 10, 11, 12]  
 
For large-scale, population-based genetic testing to become feasible and practical it is 
necessary to move away from the ‘traditional face-to-face genetic counselling’ (TC)[13, 14] 
approach, which is cost intensive requiring significant health professional time. At present 
there is no established model for providing pre-test genetic counselling for genetic-testing on 
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a population basis.[15] We hypothesised that using a DVD (audio-visual tool) could 
significantly reduce the duration and increase cost-efficiency compared with traditional face-
to-face counselling, while being non-inferior in terms of knowledge gained, counselling 
satisfaction, risk perception and equivalent in uptake of genetic testing. We report on 
outcomes from the only RCT that we are aware of comparing TC and DVD-based genetic 
counselling (DVD-C) approaches in an unselected population-based setting, undertaken 
during recruitment to the GCaPPS study.  
 
Methodology 
Cluster randomised non-inferiority trial set within GCaPPS (ISRCTN73338115). Inclusion 
criteria: (a)individuals >18years, (b)AJ ethnicity Exclusion criteria: (a)known BRCA1/2 
mutation, (b)previous BRCA1/2 testing, (c)first-degree relative(FDR) of a BRCA1/2 carrier. 
All volunteers received non-directive pre-test genetic-counselling regarding genetic-testing 
for AJ BRCA1/2 founder-mutations. Genetic counselling was undertaken by a qualified 
genetic-counsellor with clinical/counselling supervision provided by a Regional Genetics 
Centre and a clinical-fellow experienced in cancer-genetics risk-assessment and 
management. It was structured to meet the goals of genetic counselling,[16, 17, 18] 
covering: interpretation of FH, knowledge about risk, inheritance, management options, 
advantages, disadvantages and psychosocial implications to promote informed choice and 
adaptation. 
 
Recruitment clinics (clusters) were randomised to TC and DVD-C approaches. 
Randomisation of clinics was essential for logistic, organisational and pragmatic reasons. 
There was an initial DVD development process from Nov-2008 to Jan-2009. This study 
reports on genetic-counselling outcomes of clinics randomised from Feb-2009 until end of 
recruitment (July-2010) using the final DVD version. Randomisation was undertaken by a 
computer generated random number algorithm. Participants were blinded to the type of 
genetic-counselling when making an appointment. Appointments were made and 
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randomisation implemented by the study administrator independent of the counsellors. DVD-
C approach involved a DVD presentation (in the recruitment clinic) to small groups of 
volunteers (2-5) at a time. DVD-C volunteers subsequently saw a genetic counsellor for an 
individual genetic-counselling session (post-DVD) at the same appointment. Participants in 
the TC-group underwent face-to-face genetic-counselling only. FH and baseline 
questionnaires were collected prior to the DVD presentation (DVD-C) or prior to seeing the 
genetic counsellor (TC-group). Time taken for genetic-counselling was documented. Post-
counselling questionnaires were filled and collected after the genetic-counselling session. 
Individuals deciding to undergo BRCA1/2 genetic-testing were consented after genetic-
counselling.  
 
Outcomes: included uptake of genetic testing, change in cancer risk perception, increase in 
knowledge, counselling time and counselling satisfaction. 
Secondary outcomes: relevance, satisfaction, adequacy, emotional impact and improvement 
of understanding with the DVD; and cost-minimisation analysis. 
A baseline questionnaire assessed FH and socio-demographic characteristics. Knowledge 
was assessed by a specially developed 10-item (True=1/False=0) questionnaire 
(supplementary table-S1) at baseline and post genetic-counselling. Satisfaction with genetic-
counselling was assessed post-counselling by the validated 6-item Genetic-Counselling-
Satisfaction-Scale (GCSS): 5-point likert-scale (strongly-disagree=1, strongly-agree=5) for 
each item, maximum score=30.[19, 20] Cancer risk perception was measured on a 
previously used 0-100 scale at baseline and post-counselling.[21] A DVD-evaluation 
questionnaire (supplementary table-S2) assessed DVD impact (secondary outcomes) from 
May-2009 till July-2010. This was completed by DVD-C volunteers after watching the DVD 
and before meeting the genetic counsellor. Development of the knowledge questionnaire 
and DVD are descried in supplementary tables S3 and S4 respectively. 
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Participants: were recruited from the North-London Jewish community. Recruitment was 
based on self-referral. Study flyers were made available through community charities, a 
high-street pharmacy (Boots) and web-site (www.gcapps.org). Eligible individuals who 
registered with the study team were sent a detailed trial information booklet. Genetic-
counselling was undertaken at high-street/community-based centres outside a hospital 
setting.  
 
Statistical Analysis: 
Statistical analyses were undertaken in ‘Stata-13.0’ (Stata-Corp-LP, Texas, USA).  
Baseline characteristics were calculated using descriptive statistics. Chi-square tests 
compared categorical variables and t-Test(parametric) and Mann-Whitney(non-parametric) 
tests compared continuous outcome variables between two independent samples.  
Random-effects models that included a random intercept term for each cluster (clinic) 
compared outcomes between TC and DVD-C groups, and were adjusted for potential 
confounders:  FH (high/low-risk), age, gender, parity, income, education and marital status. 
The total knowledge-score was calculated as a sum of True=1 and False=0 for all 10 
questions. Sensitivity analysis for knowledge-scores was undertaken by (a)correcting final 
score to reflect proportion of valid questions answered and (b)assigning a score=‘0’ for 
missing answers. As the GCSS-scores were highly skewed with a significant peak at 30, the 
transformation |𝐺𝐺𝐺𝐺 𝑠𝑠𝑠𝑠𝑠 − 30| was considered. The resulting data distribution was 
approximated by a zero-inflated negative binomial-regression model, adjusted with the same 
confounders. Per-protocol and intention-to-treat analysis were evaluated for outcomes of 
DVD-C and TC groups. A sensitivity analysis with multivariate imputation using chained 
equations (MICE)[22] for missing data was undertaken for all outcomes. MICE iteratively 
simulates from suitable univariate imputation models that are fully conditional on all selected 
predictor variables, until convergence is reached. 50 fully imputed datasets were created to 
generate valid estimates and standard errors, and produce correct statistical inference. 
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Non-inferiority analysis is needed to determine if DVD-C is not worse than the current 
standard (TC) by an acceptable amount. A one-sided 97.5%CI was used to determine non-
inferiority for cancer risk perception, increase in knowledge and counselling satisfaction. 
Non-inferiority was established when the 97.5%CI did not cross the non-inferiority margin. A 
two-sided 95%CI was used to test equivalency of genetic testing uptake as the aim of 
genetic-counselling is informed decision making rather than to increase/decrease testing. A 
superiority analysis was undertaken for counselling time.  
. 
The non-inferiority margins were based on clinically meaningful changes where available or 
set at no more than 0.5S.D worse than that for TC from prior studies[19, 23] or data 
collected during initial counselling undertaken from Nov-2008 to Jan-2009. The non-
inferiority margin for knowledge gain=1 unit (minimum possible change on the scale, S.D=3); 
GCSS= 2 units(S.D=5.6); risk perception= 7(S.D=23.7). A +/- 10% equivalence margin was 
used for uptake of testing.  
 
The sample size was adjusted by a variance inflation factor calculated for the intra-class 
correlation(ICC) from clustering. Sample size= K*n/[1+(n-1)*ICC]; where K=number of 
clusters, n=cluster-size, ICC=intra-class correlation coefficient. This was further increased by 
10% to adjust for relative efficiency between varying and equal cluster sizes.[24] Assuming a 
mean cluster size=5, ICC=0.1, the adjusted sample-size= (original sample)x1.54. 
The total sample sizes needed for 80%power to detect ‘equivalence’ of uptake of 
testing=830 and ‘non-inferiority’ for knowledge=437, counselling satisfaction=382, risk 
perception=554. Sample size for 15min reduction in counselling time (S.D=9.9)=37 and for 
non-inferiority margin of 0.5SD of counselling time=265. Based on the final sample size of 
936, cluster size=3.6, uptake of testing=89%, the study has >90% power for determining 
equivalence of uptake (ICC=0.21) and >95%power for establishing non-inferiority of 
knowledge gain (ICC=0.007), counselling satisfaction (ICC=0.0005), risk perception 
(ICC=0.053); and superiority for counselling time (ICC=0.15) 
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Cost-minimisation analysis: was undertaken for TC and DVD-C approaches. The costs of 
filming the DVD=£300/- and burning a blank DVD=£0.60. The per-person cost=[DVD cost 
(unit-cost=£((300/409)+0.60) per-volunteer) + genetic-counselling cost]. The unit cost 
assumed for genetic-counselling=£44/hour of client contact and the cost assumed for a 
psychologist appointment (if needed)=£73/hour face-to-face contact (from PSSRU Unit costs 
of Health-&-Social Care 2010[25]).  
 
Patient / Community involvement 
The study was preceded by an extensive broad based consultation / engagement with all 
sections of the Jewish community which lasted almost a year (Supplementary table-S5).  
 
RESULTS 
Between Feb-2009 and July-2010, 936 people underwent genetic-counselling in GCaPPS 
and were cluster randomised by recruitment clinics (256 Clusters) to TC (134 clusters, 
n=527) and DVD-C (122 clusters, n=409) groups. The mean cluster size=3.6 (TC=3.8, DVD-
C=3.4). Baseline characteristics of participants were not significantly different between these 
groups (Table-1). The mean age of participants was 53.9(S.D15) years; 66.8% were women 
and 33.2% men. Our findings suggest a significant proportion of the AJ population are 
interested in BRCA1/2 testing and find it acceptable. Most(89%) of participants opted for 
genetic-testing following counselling. The uptake of testing rates and means(S.D) for 
knowledge, GCSS, counselling time and risk perception are given in Table-1. The consort 
flow-chart is given in Figure-1.  
 
We found DVD-C was non-inferior to TC for increase in knowledge (d=-0.07; lower 
97.5%CI=-0.41), counselling satisfaction (d=-0.38, 97.5%CI=1.2) and change in risk-
perception (d=0.08, upper 97.5%CI=3.1) (Figure-2, Table-2). Group differences and 
97.5%CIs did not cross non-inferiority margins. Sensitivity analysis for knowledge scores 
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and use of zero-inflated negative binomial-regression for GCSS scores gave the same 
results of DVD-C being non-inferior to TC. DVD-C was equivalent to TC for uptake of genetic 
testing (d=-3%, Lower/Upper 97.5%CI= -7.9%/1.7%), (Figure-3, Table-2). DVD-C was 
superior to TC in terms of counselling-time leading to 20.5(95%CI=18.7,22.2) minutes 
reduction in counselling time (p<0.005)(Figure-3, Table-2). Sensitivity analysis following 
multiple imputation of missing data also showed similar results (Table-2). 
 
Baseline knowledge level was significantly associated with decreasing age, and increasing 
levels of income and education, but independent of FH, gender, marital status and having 
children(Table-3). Overall genetic-counselling led to a significant increase in knowledge 
scores(p<0.0005).  
 
Responses (n=316) to the DVD-evaluation questionnaire are given in Table-4. 98% people 
were satisfied with the overall information, amount of information and DVD length. 13% felt 
certain parts required more detailed explanation. Only 2% felt some parts could be left out 
(supplementary table-S5). 95% would recommend the DVD to others and 85-89% indicated 
it improved their understanding of risks/benefits/implications and purpose of genetic-testing. 
Emotionally, 77% felt reassured; 87%-95% felt no significant degree of worry/concern/upset; 
11% felt somewhat worried/concerned, 3% somewhat upset, and 1.3% ‘quite–a–lot’ 
worried/concerned after watching the DVD.  Table-5 summarises responses on parts making 
people feel worried/concerned/upset/reassured.  
 
The total genetic-counselling cost-estimate=£7,786.65(£19/volunteer) for DVD-C and 
£17,306.68(£33/volunteer) for TC groups. The reduction in face-to-face health professional 
consultation time with the DVD translated into a total cost difference=£9,520.03. DVD-based 
counselling led to a cost-saving= £14/volunteer counselled. Although the cost 
minimisation of £14/volunteer may seem to be small in individual terms, when extrapolated 
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across a whole population it actually amounts to quite a substantial saving for the health 
care system. 
 
DISCUSSION 
To the best of our knowledge this is the first RCT to report on systematic pre-test genetic-
counselling in a low-risk population (unselected for FH) of men and women undergoing 
BRCA1/2 mutation testing. The finding that DVD-C is not inferior to TC with respect to 
increase in knowledge, risk perception or counselling satisfaction; equivalent in uptake of 
testing and more cost-efficient (cost-saving=£14/volunteer) is of great importance and 
suggests that DVD-C can be used as an effective and efficient alternative to traditional pre-
test genetic-counselling.  
 
Group genetic-counselling is reported to reduce the duration of counselling in high-risk 
populations,[8] but this is the first report of using a DVD in this situation. DVD is an audio-
visual tool with several advantages. It can be distributed/accessed by post, the web, GP 
surgeries, community centres or other high-street sources and watched by people prior to 
their genetics appointment. Unlike group/telephone counselling it does not require a health 
professional to deliver the educational material. Printed educational material is also effective 
in increasing knowledge and facilitating decision making.[26, 27] We did not directly 
compare a printed decision aid with a DVD in this study. Pre-test genetic counselling 
reduces distress, improves patients’ risk perception[28] and currently remains part of 
international guidelines for genetic testing.[5] Although no pre-test genetic-counselling was 
undertaken in two single arm contemporaneous Canadian[2] and Israeli[29] population 
studies, post-test counselling was provided, and good satisfaction reported by participants 
with the testing process. Such an approach of ‘no pre-test counselling’ or only ‘post-test 
counselling’ has not yet been directly compared to TC in a randomised trial. 
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For population-based testing to be feasible, newer models for providing information for 
informed decision making prior to genetic-testing are necessary, which need to be properly 
evaluated in well-designed trials and ideally compared to the gold-standard of TC. While we 
have demonstrated a viable DVD-based model, other models are also being explored/ 
developed. Telephone genetic-counselling has been successfully used for triaging women 
from high-risk families for TC[10] and disclosure of test result.[9, 30, 31] Three RCTs 
compared telephone counselling to TC in high-risk women attending genetics clinics, No 
difference in satisfaction[32] was reported in one. Two were non-inferiority trials and found 
telephone counselling was non-inferior to TC,[11, 12] though lower testing uptake was 
reported in one.[11] Telegenetics has been compared to TC in a RCT and reported to cost 
less with no difference in satisfaction though it was associated with 10% lower 
attendance.[33] Telephone counselling/ telegenetics have not yet been evaluated in a low-
risk population unselected for FH. Newer models like mainstreaming counselling by the non-
cancer genetics professional community[34] or trained nurse specialists[35] are currently 
being explored in clinical practice, but have not yet been directly compared to TC or other 
approaches in a RCT. It is likely that different models/pathways may be needed for different 
populations and different countries or healthcare systems. Further well-designed high-quality 
research is needed in this area. 
 
The strengths of this report include the cluster randomised design, non-inferiority analysis, 
community-based model for undergoing genetic-testing, and a high questionnaire response 
rate (73-100%). The differences in number of volunteers between the two study arms is 
explained by the randomisation of clinics (not volunteers), varying clinic times and 
differences in clinic sizes. But as expected, the baseline characteristics of the groups were in 
balance (table-1). Lack of qualitative data may be considered a weakness and restriction to 
AJ participants may limit generalizability to other populations. We were also unable to 
analyse long term outcomes post-disclosure of the test result and this may be a limitation of 
the analysis. We did not include the 15 minute patient time taken to watch the DVD in the 
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cost-minimisation analysis because our analysis covers a health care perspective in line with 
NICE methods guidance and therefore as per NICE guidance patient costs are excluded. 
Besides, in practice we would expect patients to have watched the DVD before attending for 
a genetic counselling session. We guaranteed compliance and maximised questionnaire 
response by making people watch the DVD prior to counselling. Hence, in the future, when 
the DVD is delivered at home, it it is important to ensure that people do watch the DVD at 
home prior to attending the genetic counselling session to ensure generalisability of results. 
 
The high genetic-testing uptake rate found in our study has also been reported by others.[2, 
36, 37] This may also be a function of a self-selected population, and/or non-directive 
informative pre-test counselling received by participants. Our knowledge questionnaire was 
able to detect changes in knowledge (sensitivity-to-change). The increase in knowledge 
following pre-test counselling found in a low-risk population is similar to previous reports 
from high-risk populations.[26, 38, 39] Older studies reported lower levels of knowledge 
about genetic-testing and understanding of cancer risk.[26, 39] However, our relatively 
higher mean baseline-score (>7) suggests that the average person coming forward for 
BRCA1/2 testing today may have greater levels of awareness/knowledge which is 
reassuring. The lack of difference in knowledge scores between those with and without a 
strong FH of cancer re-emphasises this point and is contrary to previous findings of an 
association between knowledge and FH of cancer.[38] The high baseline levels of 
knowledge may be a reflection of number of factors such as (a) self-selected trial 
participants, (b) the higher education and income levels known to be prevalent in the UK 
Jewish community compared to the rest of the non-Jewish general population, and (c) ever 
increasing public information and awareness on this issue. Our finding that level of 
knowledge is associated with education and income is consistent with earlier reports,[38, 40] 
and with the positive correlation (Spearman’s-rho=0.3, p<0.005) between income and 
education levels, expected in a general population. Younger people had greater knowledge 
about genetic-testing than older people. To the best of our knowledge this has not been 
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reported before. Factors that could have contributed to this include greater awareness of 
genetics, its recent incorporation into school curriculums, proactive behaviour and better 
access to sources of information in younger age groups.  
 
Decision making where each option has benefits/risks that people may value differently can 
be a difficult process. Overall our DVD was well received with high satisfaction levels, and 
enabled people to make specific, deliberated choices appropriate for them. The increase in 
knowledge is consistent with the effectiveness of the DVD in providing relevant information, 
and improving the understanding of purpose/benefits/risks/implications related to genetic-
testing. Getting the right balance between DVD-length and amount of information provided is 
challenging. The 98% satisfaction with length/information, 88% feeling no need for further 
explanation and 95% willingness to recommend it suggests our 15minute DVD struck the 
right balance for most people. A longer/more detailed DVD would yield small improvements, 
while greatly increasing the proportion of disaffected people.[7] That the same 
information/content on a topic generated different reactions (reassurance/worry) suggests 
the DVD helped facilitate variable responses consistent with individual personal values. 
Need for more information on insurance/risks/inheritance highlighted by a small proportion 
represent areas for further development. The DVD quality can also be improved by 
incorporating qualitative data and using better production, film making and editing facilities.  
 
The ability to identify 50% additional carriers, lack of psychological harm and cost-
effectiveness of population testing for BRCA1/2 mutations in AJ individuals[3, 4, 29] calls for 
changing the clinical paradigm to population-testing for BRCA1/2 founder mutations in this 
population. DVD-based counselling approach is an effective, acceptable, non-inferior and 
cost-efficient alternative to TC and could be implemented for population testing in Ashkenazi 
Jews. This can generate cost savings which is relevant for health authorities and 
commissioners of genetic-counselling services and could enable more resources being 
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directed to individuals who have difficulty coping with the genetic-test result and/or needing 
greater support from genetics services following genetic-testing.  
 
Advances in high throughput genetic-testing technology, computational analytics and falling 
costs have made non-AJ general population testing technically feasible.[41, 42] The 
identification of newer moderate penetrance genes (RAD51C/RAD51D/BRIP1),[43, 44, 45] 
and availability of panel testing will lead to an ever increasing demand for genetic services 
with newer challenges for pre-test education and genetic-counselling. Future research needs 
to compare telegenetics, telephone counselling, use of dial-in/web-based helplines, web 
apps along with DVD/other decision tools to identify/develop cost-efficient mass-based 
strategies to optimise education and facilitate informed decision making without negatively 
affecting satisfaction, knowledge, or psychological well-being in the general non-AJ 
population. A move away from TC is necessary to achieve the full benefit of genomic 
advances to deliver predictive, preventive, personalized, and participatory(P4) medicine for 
cancer prevention. 
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Figure 1: Consort Flow Chart for Recruitment to GCaPPS 
 
BL- Baseline, PC- Post Counselling, Couns- counselling  
Reasons for exclusion (ineligible volunteers): first degree relative of BRCA1/2 carrier (n=4), 
did not have 4 Ashkenazi Jewish grandparents (n=2), already had BRCA1/2 testing (n=1). 
The baseline questionnaire response rate was 100%. The post-counselling questionnaire 
response rate was 74% for traditional counselling) and 73% for DVD-counselling groups. 
The number of responses received for different outcomes are given in the questionnaire box. 
 
 
Figure 2: Non-Inferiority Outcomes for Increase in Knowledge, Counselling 
Satisfaction and Risk perception 
 
This figure shows outcomes and non-inferiority margins for difference between DVD-based 
counselling (DVD-C) and traditional face-to-face genetic counselling (TC) groups for 
increase in knowledge (Fig 2a), counselling satisfaction (Fig 2b) and cancer risk perception 
(Fig 2c). Random-effects models adjusted for covariates of FH (high/low risk), age, gender, 
parity, income, education and marital status were used to compare outcomes between TC 
and DVD-C groups. A one-sided 97.5%CI was used to determine non-inferiority for increase 
in knowledge (Fig 2a), counselling satisfaction (Fig 2b) and cancer risk perception (Fig 2c).  
The x-axis shows the adjusted mean difference (DVD-C - TC) and 97.5% Confidence Limit. 
Non-inferiority is established when the 97.5% CI (red line in the figure) does not cross the 
non-inferiority margin (black line in the figure). 
 
 
Figure 3: Equivalence analysis for Uptake of testing and Superiority analysis 
for counselling time 
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This figure shows outcomes of difference in uptake of testing with equivalence margins 
(Figure 3a) and counselling time with superiority analysis (Figure 3b) between DVD-based 
counselling (DVD-C) and traditional face-to-face genetic counselling (TC) groups. Random-
effects models adjusted for covariates of FH (high/low risk), age, gender, parity, income, 
education and marital status were used to compare outcomes between TC and DVD-C 
groups. Figure 3a: A two-sided 97.5%CI was used to determine equivalence for uptake of 
testing.  Equivalence was established when the 97.5% CI on either side (red line in the 
figure) did not cross the non-inferiority margin on either side (black line in the figure). Figure 
3b: The CIs for difference in counselling time (horizontal red line) lie well to the left of the 
superiority margin (vertical black line) indicating DVD-C is superior to TC. 
 
 
Supplementary Table S1- Knowledge Questionnaire 
 
Supplementary Table S2- DVD Evaluation Questionnaire 
 
Supplementary Table S3- Development of Knowledge Questionnaire 
 
Supplementary Table S4- Development of DVD 
 
Supplementary table-S5- Parts of the DVD requiring more details or which 
could be left out 
 
 
 
 
  
23 
 
Table-1: Comparison of Traditional face-to-face (TC) and DVD-based 
counselling (DVD-C) groups 
 
    
Traditional 
face-to-face 
(TC) 
DVD-based 
(DVD-C) 
  n 527 409 
 Number of Clusters 134 122 
 Mean Cluster Size (S.D) 3.8 (2) 3.4 (2.1) 
Age Age in years (S.D) 53.9 (15.1) 53.9 (14.9) 
Marital Status 
Single 43/520 (8.3%) 46/398 (11.6%) 
Married 400/520 (76.9%) 289/398 (72.6%) 
Cohabiting (living-with-
partner) 15/520 (2.9%) 18/398 (4.5%) 
Divorced/ Separated 30/520 (5.8%) 27/398 (6.8%) 
Widowed 32/520 (6.2%) 18/398 (4.5%) 
Children 
Have children 79.7% 83% 
Number of children (S.D) 2.3 (1.29) 2.22 (1.27) 
Gender 
Men 169 (32.1%) 142 (34.7%) 
Women 358 (67.9%) 267 (65.3%) 
Education  
No-Formal- Qualification 40/500 (8%) 25/389 (6.4%) 
GCSE, O-level, CSE 101/500 (20.2%) 71/389 (18.3%) 
NVQ1,NVQ2 5/500 (1%) 8/389 (2.1%) 
A-level,NVQ-3 52/500 (10.4%) 44/389 (11.3%) 
NVQ-4 7/500 (1.4%) 9/389 (2.3%) 
Bachelors 196/500 (39.2%) 136/389 (35%) 
Masters 82/500 (16.4%) 75/389 (19.3%) 
PhD 17 (3.4%) 21 (5.4%) 
Income (£) 
<10K 21/456 (4.6%) 21/357 (5.9%) 
10K-19.9K 32/456 (7%) 33/357 (9.2%) 
20K-29.9K 46/456 (10.1%) 36/357 (10.1%) 
30K-39.9K 50/456 (11%) 49/357 (13.7%) 
40K-49.9K 59/456 (12.9%) 33/357 (9.2%) 
≥50K 248/456 (54.4%) 185/357 (51.8%) 
FH FH of Cancer 64 (12.8%) 49 (12.9%) 
Anxiety & 
Depression 
HADS-Anxiety (S.D) 6.1 (3.5) 6.4 (3.7) 
HADS-Depresson (S.D) 2.9 (2.5) 3 (2.6) 
HADS-Total  (S.D) 9 (5.2) 9.4 (5.6) 
Genetic Testing 
Uptake 
Consented to genetic 
testing 470 (89.2%) 357 (87.3%) 
Declined genetic testing 57 (10.8%) 52 (12.7%) 
Knowledge 
Score 
Knowledge Score (BL) 7.52 (3.16) 7.71 (3.02) 
Knowledge Score (PC) 9.41 (1.28) 9.35 (1.28) 
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Counselling 
Satisfaction  GCSS score  25.59 (4.45) 25.03 (5.27) 
Counselling 
Time  
 MeanTime in minutes 
(S.D) 46 (49.7) 21.3 (8.4) 
Perceived risk 
 Baseline Risk (S.D) 50.6 (50.7) 49.6 (22.1) 
 Post Counselling Risk 
(S.D) 47.4 (23.4) 48.9 (22.7) 
  
 
FH- Family History, HADS- Hospital Anxiety and Depression Scale, S.D- standard deviation 
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Table-2: Difference in gain in knowledge, counselling satisfaction, uptake of 
testing, risk perception and counselling time between TC and DVD-C groups 
 
 
OUTCOMES FROM RANDOM EFFECTS MODELS  
Outcome 
Difference 
between 
DVD-C & TC 
Lower 
97.5% CI 
Upper 
97.5% CI 
Std. 
error 
Non-
inferiority 
Margin 
ICC 
Gain in 
Knowledge -0.07 -0.41 0.27  0.18 1 0.007 
Counselling 
Satisfaction -0.38 -1.2  0.38 0.43 2 0.0005 
Uptake of 
Testing -3% -7.9% 1.7 0.0244 +/- 10% 0.21 
Risk 
Perception 0.08 -2.9  3.1 1.55 7 0.053 
Counselling 
Time (min) -20.4 -22.2 -18.7  0.87 15*  0.15 
MULTIPLE IMPUTATION ANALYSIS 
Outcome 
Difference 
between 
DVD-C & TC 
Lower 
97.5% CI 
Upper 
97.5% CI 
Std. 
error 
Non-
inferiority 
Margin 
ICC 
Gain in 
Knowledge -0.10 -0.40 0.19 0.15 1 0.00005 
Counselling 
Satisfaction -0.47 -1.27 0.33 0.41 2 0.00003 
Uptake of 
Testing -2.5% -6.9% 2.04% 2.30% +/- 10% 0.26 
Risk 
Perception -0.04 -2.5 2.4 1.3 7 0.001 
Counselling 
Time (min) -20.6 -26.5 -14.6 3.03 15*  0.00005 
 
 
TC - Traditional face-to-face counselling, DVD-C - DVD-based counselling, ICC- intra-
class correlation coefficient, std- standard, CI- confidence interval, min- minutes 
 
*Superiority Margin  
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Table 3- Association of baseline variables with levels of Knowledge  
 
Variable 
Mean 
Knowledge 
Score (S.D) 
p value 
Marital Status 
Single 8.11 (2.39) 
0.058 
Married 7.6 (3.09) 
Cohabiting (living-with-
partner) 8.13 (2.69) 
Divorced/ Separated 7.62 (2.92) 
Widowed 6.69 (3.11) 
Children 
Yes 7.64 (2.96) 
0.794 
No 7.73 (3.05) 
Gender 
Men 7.39 (3.38) 
0.883 
Women 7.7 (2.26) 
Education 
No-Formal- Qualification 5.68 (3.75) 
p<0.005 
GCSE, O-level, CSE 7.17 (3.22) 
NVQ1,NVQ2 8 (2.54) 
A-level,NVQ-3 7.38 (3.18) 
NVQ-4 7.06 (3.35) 
Bachelors 7.94 (2.78) 
Masters 8.26 (2.40) 
PhD 8.67 (2.29) 
Income (£) 
<10K 6.98 (2.96) 
0.007 
10K-19.9K 7.73 (2.96) 
20K-29.9K 6.89 (3.68) 
30K-39.9K 7.31 (3.27) 
40K-49.9K 7.7 (2.96) 
≥50K 8.13 (2.59) 
FH Positive  
Yes 8.19 (2.33) 
0.121 
No 7.52 (3.13) 
Age Group 
Age < 30 years 8.6 (1.74) 
p<0.005 
Age 30-50 years 8.68 (1.65) 
Age 50 - 70 years 8.12 (2.16) 
Age >70 years 7.55 (2.77) 
 
 
FH- family history, S.D- standard deviation, NVQ- National Vocational Qualification 
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Table-4 – DVD Evaluation Questionnaire 
 
n=316 Very Satisfied Satisfied 
Neither 
satisfied / 
dissatisfied 
Dissatisf
ied 
Very 
dissatisfie
d 
Satisfaction with information 
provided (n=316) 74.1% 24.7% 1.30% 0% 0% 
 Too little  About right  Too much Amount of information 
provided (n=316) 0.3%  98.7%  0.9% 
 
Too 
short  About right  Too long 
Time taken to watch the 
presentation (n=315) 0%  98.4%  1.6% 
Any parts of the 
presentation need to be 
explained in more detail 
(n=315) 
Yes 13.3%  No 86.7% 
Any parts of the 
presentation that could be 
left out (n=313) 
Yes 1.9%  No 97.2% 
How much did the 
presentation improve your 
understanding of:  
Not at all Not very much Somewhat 
Quite a 
bit A lot 
Purpose of genetic testing 
(n=316) 5.4% 8.9% 24.1% 43.7% 18.0% 
Risks of genetic testing in your 
situation (n=316) 3.5% 7.6% 30.7% 39.2% 19.0% 
Benefits of genetic testing in 
your situation (n=315) 3.5% 7.6% 25.9% 41.1% 21.5% 
Implications of a positive result 
(n=314) 3.5% 6.6% 23.1% 39.6% 26.6% 
How much did the 
presentation make you feel Not at all 
Not very 
much Somewhat 
Quite a 
bit A lot 
Worried or concerned (n=314) 52.2% 34.8% 11.1% 1.3% 0% 
Reassured (n=308) 9.2% 10.8% 46.8% 21.5% 9.2% 
Upset (n=312) 82.6% 13.0% 3.2% 0% 0% 
 
Yes, I 
would  
I’m not 
sure  
No, I 
would not 
Would you recommend the 
presentation to others 
(n=315) 
94.9%  4.4%  0.3% 
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Table 5- Parts of the DVD making people feel worried, upset or reassured 
 
Parts leading to feeling worried, upset or reassured n (%) 
Nothing Nothing 6 (1.9%) 
Worried 
3 months to result 1 (0.3%) 
may not be tested 2 (0.6%) 
general concern 2 (0.6%) 
insurance 3 (1%) 
high probability of cancer 3 (1%) 
impact on children/ family 3 (1%) 
implications 1 (0.3%) 
concentration not 100% 1 (0.3%) 
Upset increased gene frequency in AJ 2 (0.6%) 
Reassured 
clear presentation 8 (2.5%) 
logical balanced view 2 (0.6%) 
Presenter has excellent skills 1 (0.3%) 
positive video 2 (0.6%) 
factual 2 (0.6%) 
statistics 2 (0.6%) 
Insurance information 1 (0.3%) 
ability to participate 1 (0.3%) 
implications 2 (0.6%) 
general reassurance 4 (1.3%) 
available help, options 4 (1.3%) 
Follow Up available 2 (0.6%) 
Other Comments 
difficult decision 1 (0.3%) 
unemotional  1 (0.3%) 
statistical 1 (0.3%) 
presenter- needs better eye 
contact, body language 1 (0.3%) 
surprised not worried about 
risks 1 (0.3%) 
need time to absorb facts 1 (0.3%) 
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